Andrew Cittadine's Insider Trades & SAST Disclosures
Andrew Cittadine's most recent trade in Monopar Therapeutics Inc was a trade of 43,445 Stock Options done . Disclosure was reported to the exchange on March 4, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Andrew Cittadine.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
|
Monopar Therapeutics Inc
|
Andrew J. Cittadine | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2025 | 43,445 | 43,445 | - | - | Stock Options | |
|
Monopar Therapeutics Inc
|
Andrew J. Cittadine | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2025 | 40,581 | 51,655 | - | - | Restricted Stock Units | |
|
Monopar Therapeutics Inc
|
J. Andrew Cittadine | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Dec 2024 | 1,790 | 11,074 | - | - | Restricted Stock Units | |
|
Monopar Therapeutics Inc
|
Cittadine J. Andrew | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Dec 2024 | 1,790 | 41,659 (0%) | 0% | - | Common Stock | |
|
Monopar Therapeutics Inc
|
Cittadine J. Andrew | Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.00 per share. | 31 Dec 2024 | 721 | 40,938 (0%) | 0% | 22 | 15,862 | Common Stock |
|
Monopar Therapeutics Inc
|
Andrew J. Cittadine | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Sep 2024 | 1,791 | 40,404 (0%) | 0% | - | Common Stock | |
|
Monopar Therapeutics Inc
|
Andrew J. Cittadine | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Sep 2024 | 1,791 | 12,864 | - | - | Restricted Stock Units | |
|
Monopar Therapeutics Inc
|
Andrew J. Cittadine | Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.74 per share. | 30 Sep 2024 | 535 | 39,869 (0%) | 0% | 6.7 | 3,606 | Common Stock |
|
Monopar Therapeutics Inc
|
Andrew J. Cittadine | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jun 2024 | 8,952 | 73,271 | - | - | Restricted Stock Units | |
|
Monopar Therapeutics Inc
|
Andrew J. Cittadine | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jun 2024 | 8,952 | 195,084 (1%) | 0% | - | Common Stock | |
|
Monopar Therapeutics Inc
|
Andrew J. Cittadine | Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.73 per share. | 30 Jun 2024 | 2,019 | 193,065 (1%) | 0% | 0.7 | 1,476 | Common Stock |
|
Monopar Therapeutics Inc
|
Andrew J. Cittadine | Chief Operating Officer | Purchase of securities on an exchange or from another person at price $ 0.74 per share. | 18 Jun 2024 | 20,508 | 186,132 (1%) | 0% | 0.7 | 15,254 | Common Stock |
|
Monopar Therapeutics Inc
|
Andrew J. Cittadine | Chief Operating Officer | Purchase of securities on an exchange or from another person at price $ 0.86 per share. | 18 Jun 2024 | 12,000 | 165,624 (1%) | 0% | 0.9 | 10,320 | Common Stock |
|
Monopar Therapeutics Inc
|
Andrew J. Cittadine | Chief Operating Officer | Purchase of securities on an exchange or from another person at price $ 0.90 per share. | 13 Jun 2024 | 12,000 | 153,624 (1%) | 0% | 0.9 | 10,799 | Common Stock |
|
Monopar Therapeutics Inc
|
Andrew J. Cittadine | Chief Operating Officer | Purchase of securities on an exchange or from another person at price $ 0.93 per share. | 13 Jun 2024 | 12,000 | 141,624 (1%) | 0% | 0.9 | 11,176 | Common Stock |
|
Monopar Therapeutics Inc
|
Andrew J. Cittadine | Chief Operating Officer | Purchase of securities on an exchange or from another person at price $ 0.91 per share. | 13 Jun 2024 | 12,000 | 129,624 (1%) | 0% | 0.9 | 10,920 | Common Stock |
|
Monopar Therapeutics Inc
|
Andrew J. Cittadine | Chief Operating Officer | Purchase of securities on an exchange or from another person at price $ 0.76 per share. | 03 Jun 2024 | 12,000 | 105,624 (0%) | 0% | 0.8 | 9,120 | Common Stock |
|
Monopar Therapeutics Inc
|
Andrew J. Cittadine | Chief Operating Officer | Purchase of securities on an exchange or from another person at price $ 0.78 per share. | 03 Jun 2024 | 12,000 | 117,624 (1%) | 0% | 0.8 | 9,360 | Common Stock |
|
Monopar Therapeutics Inc
|
Andrew J. Cittadine | Chief Operating Officer | Purchase of securities on an exchange or from another person at price $ 0.64 per share. | 29 May 2024 | 12,000 | 93,624 (0%) | 0% | 0.6 | 7,732 | Common Stock |
|
Monopar Therapeutics Inc
|
Andrew J. Cittadine | Chief Operating Officer | Purchase of securities on an exchange or from another person at price $ 0.64 per share. | 29 May 2024 | 12,000 | 69,624 (0%) | 0% | 0.6 | 7,643 | Common Stock |
|
Monopar Therapeutics Inc
|
Andrew J. Cittadine | Chief Operating Officer | Purchase of securities on an exchange or from another person at price $ 0.64 per share. | 29 May 2024 | 12,000 | 81,624 (0%) | 0% | 0.6 | 7,676 | Common Stock |
|
Monopar Therapeutics Inc
|
Andrew J. Cittadine | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 May 2024 | 25,000 | 25,000 | - | - | Stock Options | |
|
Monopar Therapeutics Inc
|
Andrew J. Cittadine | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2024 | 8,952 | 82,223 | - | - | Restricted Stock Units | |
|
Monopar Therapeutics Inc
|
Andrew J. Cittadine | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2024 | 8,952 | 60,722 (0%) | 0% | - | Common Stock | |
|
Monopar Therapeutics Inc
|
Andrew J. Cittadine | Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.68 per share. | 31 Mar 2024 | 3,098 | 57,624 (0%) | 0% | 0.7 | 2,110 | Common Stock |
|
Monopar Therapeutics Inc
|
Andrew Cittadine | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Dec 2023 | 8,952 | 54,868 (0%) | 0% | - | Common Stock | |
|
Monopar Therapeutics Inc
|
Cittadine Andrew | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Dec 2023 | 8,952 | 91,175 | - | - | Restricted Stock Units | |
|
Monopar Therapeutics Inc
|
Cittadine Andrew | Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.34 per share. | 31 Dec 2023 | 3,098 | 51,770 (0%) | 0% | 0.3 | 1,054 | Common Stock |
|
Monopar Therapeutics Inc
|
Andrew Cittadine | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jun 2023 | 13,841 | 43,644 (0%) | 0% | - | Common Stock | |
|
Monopar Therapeutics Inc
|
Andrew Cittadine | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jun 2023 | 13,841 | 109,080 | - | - | Restricted Stock Units | |
|
Monopar Therapeutics Inc
|
Andrew Cittadine | Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.86 per share. | 30 Jun 2023 | 4,057 | 39,587 (0%) | 0% | 0.9 | 3,469 | Common Stock |
|
Monopar Therapeutics Inc
|
Andrew Cittadine | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2023 | 4,063 | 44,687 | - | - | Restricted Stock Units | |
|
Monopar Therapeutics Inc
|
Andrew Cittadine | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2023 | 4,063 | 30,957 (0%) | 0% | - | Common Stock | |
|
Monopar Therapeutics Inc
|
Andrew Cittadine | Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.39 per share. | 31 Mar 2023 | 1,154 | 29,803 (0%) | 0% | 1.4 | 1,604 | Common Stock |
|
Monopar Therapeutics Inc
|
Andrew Cittadine | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2023 | 102,688 | 102,688 | - | - | Stock Options | |
|
Monopar Therapeutics Inc
|
Andrew Cittadine | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2023 | 78,234 | 126,984 | - | - | Restricted Stock Units | |
|
Monopar Therapeutics Inc
|
Andrew Cittadine | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Dec 2022 | 4,062 | 48,750 | - | - | Restricted Stock Units | |
|
Monopar Therapeutics Inc
|
Andrew Cittadine | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Dec 2022 | 4,062 | 28,300 (0%) | 0% | - | Common Stock | |
|
Monopar Therapeutics Inc
|
Andrew Cittadine | Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.37 per share. | 31 Dec 2022 | 1,406 | 26,894 (0%) | 0% | 2.4 | 3,332 | Common Stock |
|
Monopar Therapeutics Inc
|
Andrew Cittadine | Chief Operating Officer | Purchase of securities on an exchange or from another person at price $ 3.15 per share. | 14 Nov 2022 | 10,000 | 24,238 (0%) | 0% | 3.2 | 31,500 | Common Stock |
|
Monopar Therapeutics Inc
|
Andrew Cittadine | Chief Operating Officer | Purchase of securities on an exchange or from another person at price $ 3.00 per share. | 14 Nov 2022 | 6,053 | 14,238 (0%) | 0% | 3 | 18,159 | Common Stock |
|
Monopar Therapeutics Inc
|
Andrew Cittadine | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Sep 2022 | 4,063 | 52,812 | - | - | Restricted Stock Units | |
|
Monopar Therapeutics Inc
|
Andrew Cittadine | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Sep 2022 | 4,063 | 9,376 (0%) | 0% | - | Common Stock | |
|
Monopar Therapeutics Inc
|
Andrew Cittadine | Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.52 per share. | 30 Sep 2022 | 1,191 | 8,185 (0%) | 0% | 1.5 | 1,810 | Common Stock |
|
Monopar Therapeutics Inc
|
Andrew Cittadine | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jun 2022 | 8,125 | 56,875 | - | - | Restricted Stock Units | |
|
Monopar Therapeutics Inc
|
Andrew Cittadine | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jun 2022 | 8,125 | 8,125 (0%) | 0% | - | Common Stock | |
|
Monopar Therapeutics Inc
|
Andrew Cittadine | Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.30 per share. | 30 Jun 2022 | 2,812 | 5,313 (0%) | 0% | 2.3 | 6,465 | Common Stock |
|
Monopar Therapeutics Inc
|
Andrew Cittadine | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2021 | 30,000 | 30,000 | - | - | Stock Options | |
|
Monopar Therapeutics Inc
|
Andrew Cittadine | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2021 | 70,000 | 70,000 | - | - | Stock Options |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges